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ess: roumar26@yahoo.cSummary An increased seroprevalence of Helicobacter pylori (H. pylori) and
especially of the high virulent cytotoxin-associated gene-A (CagA) positive strains
has been found in several extragastroduodenal pathologies, characterized by
activation of inflammatory mediators. Moreover, it has been reported that the risk
of chronic bronchitis may be increased in H. pylori infected patients. The aim of the
present study was to assess the seroprevalence of H. pylori and in particular of CagA-
positive virulent strains in patients with chronic obstructive pulmonary disease
(COPD). We evaluated 126 COPD patients (88 males and 38 females, aged 61.378.1
years) and 126, age and sex-matched, control subjects. All subjects enrolled
underwent an enzyme-linked immunosorbent assay (ELISA) IgG serologic test for H.
pylori and CagA protein. The prevalence of H. pylori infection in patients and
controls was 77.8% and 54.7%, respectively (Po0:001) and that of CagA-positive H.
pylori infection was 53.9% and 29.3%, respectively (Po0:001). Moreover, COPD
patients had a significantly increased mean serum concentration of both anti-H.
pylori IgG (118.3724.4 vs. 61.9712.9 U/ml, Po0:001) and anti-CagA IgG antibodies
(33.873.4 vs. 19.071.5U/ml, Po0:001). Finally, no statistically significant
difference, as regards the spirometric values, was detected between H. pylori
infected COPD patients and uninfected ones. In conclusion, H. pylori infection may
be associated with COPD. Further studies should be undertaken to clarify the
potential underlying pathogenetic mechanisms.
& 2004 Elsevier Ltd. All rights reserved.Elsevier Ltd. All rights reserved.
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Helicobacter pylori (H. pylori) is a slow-growing,
microaerophilic, gram-negative bacterium which
colonizes gastric mucosa and elicits both inflam-
matory and immune lifelong responses, with re-
lease of various bacterial and host-dependent
cytotoxic substances.1 This bacterium seems to
have a causative role in the development of chronic
gastritis,2 peptic ulcer disease,3 low-grade B-cell
lymphoma of gastric mucosa-associated-lymphoid-
tissue (MALT-lymphoma)4 and gastric cancer.5 Re-
cent studies suggest that H. pylori infection might,
also, be associated with several extragastroduode-
nal pathologies characterized by activation of
inflammatory mediators and/or induction of auto-
immunity.6–8 Therefore, increased H. pylori
seroprevalence has been found in ischemic heart
disease,9 rosacea10 and active bronchiectasis.11
In patients with ischemic heart disease, an ex-
tremely high prevalence of the cytotoxin-asso-
ciated gene-A (CagA) positive virulent strain of
H. pylori has also been reported.12 The CagA-
positive are those strains that induce increased
local and systemic, humoral and cellular inflamma-
tory response.13
It is well known that the prevalence of chronic
obstructive pulmonary disease (COPD) in peptic
ulcer patients is increased two-to-three fold,
compared with findings in ulcer-free controls.14–16
The major factor underlying this association seems
to be the impact of cigarette smoking on both
diseases. However, in 1998, a pilot study in a small
number of Italian patients showed that H. pylori
infection, per se, might be related to an high risk of
developing chronic bronchitis.17 More recently, an
epidemiological study in Danish adults suggested
that chronic bronchitis might be more prevalent in
H. pylori IgG-seropositive women than in unin-
fected ones.18 These observations prompted us to
perform a case-control study in a cohort of Greek
patients with chronic bronchitis. We found extre-
mely high H. pylori seropositivity.19 However, the
prevalence of H. pylori and especially of CagA-
positive strains (that induce increased inflamma-
tory response and have been associated with other
extraintestinal disorders), in COPD patients re-
mains still unknown.
Therefore, the aim of the present study was to
assess the seroprevalence of H. pylori and in
particular of CagA-positive virulent strains in a
cohort of COPD patients and control subjects
(outpatients with a variety of respiratory diseases).
Moreover, we evaluated the association between H.
pylori serological status and spirometric values in
patients with COPD.Methods
Patients selection
The present study was conducted at the 9th
Department of Pulmonary Medicine, ‘‘Sotiria’’
Chest Diseases Hospital (Athens, Greece). The local
ethics committee approved the study and written
informed consent was obtained from each partici-
pant. Following a predefined protocol, between
June 1, 2002 and October 31, 2003, 178 consecu-
tive patients with COPD, diagnosed according to
the Global Initiative for Chronic Obstructive Pul-
monary Disease (GOLD) guidelines, were recruited
from the outpatient clinics. Briefly, COPD was
diagnosed as ‘‘the presence of a postbronchodilator
FEV1 o80% of the predicted value in combination
with an FEV1/FVC o70% in any patient who has
symptoms of cough, sputum production, or dyspnea
and/or a history of exposure to risk factors for the
disease’’.20 Exclusion criteria were: (i) an exacer-
bation of COPD in the preceding month, as in those
cases pulmonary function does not represent base-
line levels, (ii) prior H. pylori eradication therapy,
(iii) consumption of acid-suppressive drugs or
antibiotics in the preceding 6 months and (iv) a
history of vagotomy or operation on the upper
gastrointestinal tract. A total of 52 patients were
excluded. Therefore, 126 patients were eligible for
analysis.Control subjects selection
Controls were selected randomly from 204 con-
secutive subjects with other pulmonary disorders
attending the outpatient clinics during the period
of study (bronchial asthma, respiratory infections,
lung cancer and sarcoidosis). Briefly, bronchial
asthma was diagnosed as the ‘‘presence of symp-
toms of episodic wheezing, cough and shortness of
breath responding to bronchodilators and reversi-
ble airflow obstruction documented in at least one
previous pulmonary function study’’ Exclusion
criteria for controls were: (i) a known history of
COPD, (ii) a known history of gastrointestinal tract
pathology including H. pylori infection and (iii)
consumption of acid-suppressive drugs or antibio-
tics in the preceding 6 months. Finally, we selected
126 controls from among 204 subjects (60 with
respiratory infections, 38 with lung cancer, 22 with
asthma and 6 with sarcoidosis). Control subjects
were matched with the COPD patients for sex, age
(within 2 years) and socioeconomic status. Social
class classification was based on the current
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the United Kingdom Registrar General. Assignment
to class group is determined as follows: social class
I: skilled professionals, social class II: intermediate
manual workers, social class III: skilled manual
workers, social class IV: partly skilled manual
workers and social class V: unskilled manual work-
ers. All unemployed housewives were classified
according to their husbands’ occupation.Lung function—COPD severity
In all COPD patients a complete medical history was
taken and a physical examination was performed.
Moreover, in all cases postbronchodilation spiro-
metric values (FEV1, FVC, FEV1/FVC) were mea-
sured. The best value of three maneuvers was
expressed as a percentage of the predicted value.
Finally, classification of COPD severity was per-
formed according to GOLD guidelines.20 Briefly,
three stages of COPD according to disease severity
were recognized:(I) Stage I (mild COPD) was characterized by mild
airflow limitation (FEV1/FVC o70% and
FEV1480% predicted).(II) Stage II (moderate COPD) was characterized by
worsening airflow limitation (30%o FEV1o80%
predicted) and(III) Stage III (severe COPD) was characterized by
severe airflow limitation (FEV1o30% pre-
dicted) or the presence of respiratory failure
or clinical signs of right heart failure.Table 1 Demographic data of COPD patients and
controls and spirometric values of COPD patients.
Parameters COPD
patients
(n ¼ 126)
Controls
(n ¼ 126)
P-value
Age (yr) 61.378.1 59.077.3 ns*
Male sex (%) 69.8 69.8 ns*
FEV1
y 61.9718.5
FEV1/FVC
y 63.274.8
*Not significant.
yExpressed as percentages of the predicted values.Serological parameters
All subjects enrolled (COPD patients and controls)
underwent an enzyme-linked immunosorbent assay
(ELISA) IgG serologic test for H. pylori and CagA
protein detection (HEL-P test, Park Co, Athens,
Greece), in accordance with the manufacturer’s
guidelines. The specificity and sensitivity of the
serology test, validated in our local population,
were 95% and 85%, respectively.
All results were analyzed simultaneously by
technicians who were unaware of whether the
sample belonged to cases or controls. A positive,
borderline and negative result was assigned when
the concentration of IgG antibodies against H.
pylori was greater than 25, between 20 and 25
and less than 20U/ml, respectively. Moreover,
when the concentration of IgG CagA antibodies
was greater than 7.5 U/ml, between 5.5 and 7.5 U/
ml and less than 5.5 U/ml the result was consideredas positive, borderline and negative, respectively.
Borderline results were omitted from further
analysis.
Statistical analysis
Results are expressed as mean 7 one standard
deviation (7SD). Significance of difference between
groups was assessed by unpaired Student’s t-test
for continuous variables and w2-test for propor-
tions. The statistical analysis was performed using
the SPSS program (SPSS Inc, IL, USA) and P-values
were two-tailed analyzed. P-values of less than
0.05 were considered statistically significant.Results
The demographic data of both patients and controls
are shown in Table 1.
There was no significant difference in age or sex
distribution between the two groups. Table 1 shows
also the spirometric values of patients with COPD.
Among the COPD patients, 35 (27.7%) had mild
disease (Stage I according to GOLD classification),
68 (53.9%) had moderate disease (Stage II) and 23
(18.4%) had severe COPD (Stage III).
Table 2 shows the analysis of the serological
parameters. Both anti-H. pylori IgG seropositivity
and anti-CagA IgG seropositivity were significantly
higher in COPD patients than in control subjects.
Moreover, COPD patients had a significantly in-
creased mean serum concentration of both anti-H.
pylori IgG and anti-CagA IgG antibodies.
The distribution of COPD patients according to
COPD severity was as follows: (i) Stage I (mild
COPD): 35 patients (27.7%), (ii) Stage II (moderate
COPD): 68 patients (53.9%) and (iii) Stage III (severe
COPD): 23 patients (18.4%). The spirometric values
of COPD patients in relation with H. pylori infection
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Table 2 Serological parameters in COPD patients and control subjects.
Parameters COPD patients Control subjects P-value
(n ¼ 126) (n ¼ 126)
Anti-H. pylori IgG seropositivity (%) 77.8 54.7 o0.001
Anti-H. pylori IgG level (U/ml) 118.3724.4 61.9712.9 o0.001
Anti-CagA IgG seropositivity (%) 53.9 29.3 o0.001
Anti-CagA IgG level (U/ml) 33.873.4 19.071.5 o0.001
Table 3 The spirometric values of COPD patients in relation with H. pylori infection.
Parameters H. pylori positive H. pylori negative P-value
(n ¼ 98) (n ¼ 28)
FEV1
* 61.5718.9 63.5717.9 nsy
FEV1/FVC
* 63.074.9 63.974.6 nsy
*Expressed as percentages of the predicted values.
yNot significant.
A. Roussos et al.282are shown in Table 3. No statistically significant
difference, as regards the values, was detected
between H. pylori infected COPD patients and
uninfected ones. Finally, the spirometric values did
not differ significantly between COPD patients
infected with CagA-positive strains (FEV1:
59.1719.7, FEV1/FVC: 65.4716.6) and those in-
fected with CagA-negative strains (FEV1: 62.475.1,
FEV1/FVC: 64.374.3, P: not significant).Discussion
Data in the literature on the relationship between
H. pylori infection and chronic obstructive pulmon-
ary disease (COPD) are poor. COPD had been
associated with gastroduodenal ulcer many years
before the identification of H. pylori infection as a
cause of peptic ulcer disease. Three epidemiologi-
cal studies, carried out between 1968 and 1986,
showed that the prevalence of COPD in peptic ulcer
patients was increased two-to-three fold compared
with that in ulcer-free controls.14–16 Moreover, a
follow-up study demonstrated that COPD was a
major cause of death among patients with peptic
ulcer disease.21 The reported association between
these two diseases was, originally, attributed to the
known role of cigarette smoking as an independent
factor in both ulcerogenesis and development of
COPD.22 However, two recent studies showed that a
subpopulation of COPD patients, those with chronic
bronchitis, might also have an increased prevalence
of H. pylori infection.17,19The present study is the first focused on the
seroprevalence of H. pylori and in particular of
CagA-positive virulent strains in a large population
of patients with COPD. Patients who were at risk for
COPD (STAGE 0 according to GOLD) were not
included in our study as those patients might have
only limited differences as regards lung function
with controls, a fact that might represent a
potential study limitation. According to our results,
both anti-H. pylori and anti-CagA seropositivity
were significantly higher in COPD patients than in
control subjects. The socioeconomic status, which
is related with both H. Pylori infection and risk of
COPD, is similar in the two groups. Tobacco use
could be another confounding factor. Cigarette
smoking is the most important etiologic factor of
COPD. However, data on the relationship between
H. pylori infection and smoking habits are con-
troversial. The prevalence of H. pylori infection in
smokers has been variously reported as low,23
normal,24 and high.25 In the present study, we did
not match patients and control subjects for smok-
ing habits. As the relation between smoking and H.
pylori colonization of gastric mucosa has not been
clarified yet, the possible impact of cigarette
smoking on both COPD and H. pylori infection
should be regarded as a potential study limitation.
The selection of control subjects should be
considered as another study limitation. It has been
suggested, in a few studies, that H. pylori might be
increased in a variety of respiratory disorders
including lung cancer, bronchiectasis and tubercu-
losis.8 Therefore, the selection of patients with
respiratory diseases as controls may have reduced
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the groups. However, the existed difference could
not be attributed to this selection, as a low H.
pylori seroprevalence in respiratory diseases has
not been reported yet.8
The present study has not focused on the
potential pathogenetic mechanisms underlying the
association between H. pylori infection and COPD.
This association might reflect either susceptibility
induced by common factors or a kind of causal
relationship between these diseases. As far as we
know, there are no common factors implicated in
the susceptibility to both COPD and H. pylori
infection. However, we cannot rule out this
possibility, as the predisposing conditions to H.
pylori infection have not been clarified yet.
With regard to the potential aetio-pathogenetic
role of H. pylori infection in COPD, the chronic
activation of inflammatory mediators induced by H.
pylori infection might lead to the development of
COPD. The increased prevalence of CagA positive
strains in our study population further supports this
hypothesis. It is well known that these virulent
strains stimulate the release of a variety of
proinflammatory cytokines, including Interleukin-1
(IL-1), IL-8 and tumour necrosis factor-alpha.26,27
Moreover, eradication of H. pylori leads to normal-
ization of serum cytokines levels.28 These cytokines
are also thought to be involved in the pathogenesis
of COPD.29–31 Therefore, H. pylori infection in
general and CagA-positive strains in particular
might play a proinflammatory role and co-trigger
COPD with other more specific environmental,
genetic and unknown factors. The lack of associa-
tion between spirometric values and H. pylori
infection, reported in our study, suggest that H.
pylori might have a minor role in the further
progression of the disease.
Another potential pathogenetic mechanism could
be the spilling or inhalation of H. pylori or its
exotoxins into the respiratory tract, which also
might lead to a chronic airway inflammation such as
COPD. However, as far as we know, neither
identification of H. pylori species in human bron-
chial tissue, nor isolation of H. pylori from
bronchoalveolar lavage (BAL) fluid has been
achieved yet.32
In conclusion, the present study suggests that
patients with COPD have an increased seropreva-
lence of H. pylori infection. Our results must
be confirmed in a larger number of patients.
Further studies should be undertaken to clarify
the pathogenetic mechanisms underlying the pos-
sible association between these diseases and the
effect of H. pylori eradication on the natural
history of COPD.References
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